PHO-COG-CROOP-ADVL1312; A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children Adolescents and Young Adults With Relapsed or Refractory Solid Tumors

Recruiting
1 years - 21 years
All
Phase N/A
1 Location

Brief description of study

This phase I/II trial studies the side effects and best dose of WEE1 inhibitor MK-1775 and irinotecan hydrochloride in treating younger patients with solid tumors that have come back or that have not responded to standard therapy. WEE1 inhibitor MK-1775 and irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Detailed description of study

The purpose of this study us to estimate the maximum tolerated dose (MTD) and/or recommended Phase 2 dose of MK-1775 (WEE1 inhibitor MK-1775) administered on days 1 through 5 every 21 days, in combination with oral irinotecan (irinotecan hydrochloride), to children with recurrent or refractory solid tumors; to define and describe the toxicities of MK-1775 in combination with oral irinotecan administered on this schedule; and to characterize the pharmacokinetics of MK-1775 in children with refractory cancer.

Participants will be paid for their participation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Supratentorial Promitive Neuroectodermal Tumor,Relapsed or Refractory Solid Tumors,Relapsed solid tumor,refractory solid tumor,relapsed,refractory,solid tumor,tumor,tumors,Medulloblastoma,Neuroblastoma,Supratentorial Promitive Neuroectodermal Tumor,Neuroectodermal Tumor,cancer,oncology,pediatric,kid,kids,child,children,youth,adolescent,teen,teens,teenager,teenagers,riley
  • Age: 1 years - 21 years
  • Gender: All

Inclusion Criteria
In order to be eligible to take part in this trial, patients must meet the following criteria:

  • Patients must have had histologic verification of malignancy at original diagnosis or relapse except in patients with intrinsic brain stem tumors, optic pathway gliomas, or patients with pineal tumors and elevations of cerebrospinal fluid (CSF) or serum tumor markers including alpha-fetoprotein or beta-human chorionic gonadotropin (HCG)
  • Patient's current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life

For a full list of participation criteria, please visit ClinicalTrials.gov.

Updated on 04 Aug 2024. Study ID: 1404716151

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Zip Code
Please provide your 5-digit zip code
0 0 /250
Other language

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team